Applications of Viscoelastic Testing in Breast Cancer Patients: A Systematic Review Focusing on Hypercoagulability and Free Flap Thrombosis

Abstract

Viscoelastic testing is a clinically available method to assess hypercoagulability. This systematic review aims to provide a comprehensive overview of the existing literature and the potential use of such testing in patients with breast cancer. A systematic literature search for studies investigating the application of viscoelastic testing for patients with breast cancer was conducted. Studies were included as long as they were original, peer-reviewed, and in the English language. Studies were excluded if they were review articles, did not include breast cancer patients, or if the full text was unavailable. This review identified 10 articles that met the inclusion criteria. Two of the studies utilized rotational thromboelastometry, and an additional four studies used thromboelastography, to assess hypercoagulability in patients with breast cancer. Three of the identified articles discussed the use of thromboelastometry in free flap breast reconstruction for patients with breast cancer. One study was a retrospective chart review looking at thromboelastography and microsurgical breast reconstruction. Current literature regarding the application of viscoelastic testing in breast cancer and free flap breast reconstruction is limited, with no randomized trials thus far. However, some studies suggest that there may be potential utility in viscoelastic testing to assess risk for thromboembolism in breast cancer patients, and future research in this area is warranted.

Keywords

breast cancer - viscoelastic testing - thromboelastography - thromboelastometry - ROTEM - clinical applications

Publication History

Article published online:
16 June 2023

• References

• 1 Giaquinto AN, Sung H, Miller KD. et al. Breast Cancer Statistics, 2022. CA Cancer J Clin 2022; 72 (06) 524-541
• 2 Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer 2013; 49 (06) 1404-1413
• 3 Caine GJ, Stonelake PS, Lip GYH, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002; 4 (06) 465-473
• 4 Cronin-Fenton DP, Søndergaard F, Pedersen LA. et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer 2010; 103 (07) 947-953
• 5 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
• 6 Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007; 25 (01) 70-76
• 7 Fisher B, Dignam J, Wolmark N. et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89 (22) 1673-1682
• 8 Kirwan CC, Descamps T, Castle J. Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer. Clin Transl Oncol 2020; 22 (06) 870-877
• 9 Kulkarni AR, Sears ED, Atisha DM, Alderman AK. Use of autologous and microsurgical breast reconstruction by U.S. plastic surgeons. Plast Reconstr Surg 2013; 132 (03) 534-541
• 10 Fosnot J, Jandali S, Low DW, Kovach III SJ, Wu LC, Serletti JM. Closer to an understanding of fate: the role of vascular complications in free flap breast reconstruction. Plast Reconstr Surg 2011; 128 (04) 835-843
• 11 Chang EI, Carlsen BT, Festekjian JH, Da Lio AL, Crisera CA. Salvage rates of compromised free flap breast reconstruction after recurrent thrombosis. Ann Plast Surg 2013; 71 (01) 68-71
• 12 Masoomi H, Clark EG, Paydar KZ. et al. Predictive risk factors of free flap thrombosis in breast reconstruction surgery. Microsurgery 2014; 34 (08) 589-594
• 13 Liu FC, Miller TJ, Wan DC, Momeni A. The impact of coagulopathy on clinical outcomes following microsurgical breast reconstruction. Plast Reconstr Surg 2021; 148 (01) 14e-18e
• 14 Carll T, Wool GD. Basic principles of viscoelastic testing. Transfusion 2020; 60 (Suppl. 06) S1-S9
• 15 Hartmann J, Murphy M, Dias JD. Viscoelastic hemostatic assays: moving from the laboratory to the site of care - a review of established and emerging technologies. Diagnostics (Basel) 2020; 10 (02) 118
• 16 Nguyen-Buckley C, Gao W, Agopian V, Wray C, Steadman RH, Xia VW. Major thromboembolic complications in liver transplantation: the role of rotational thromboelastometry and cryoprecipitate transfusion. Transplantation 2021; 105 (08) 1771-1777
• 17 Kamel Y, Hassanin A, Ahmed AR. et al. Perioperative thromboelastometry for adult living donor liver transplant recipients with a tendency to hypercoagulability: a prospective observational cohort study. Transfus Med Hemother 2018; 45 (06) 404-412
• 18 Tsantes AG, Papadopoulos DV, Trikoupis IG. et al. Rotational thromboelastometry findings are associated with symptomatic venous thromboembolic complications after hip fracture surgery. Clin Orthop Relat Res 2021; 479 (11) 2457-2467
• 19 Hincker A, Feit J, Sladen RN, Wagener G. Rotational thromboelastometry predicts thromboembolic complications after major non-cardiac surgery. Crit Care 2014; 18 (05) 549
• 20 Gary JL, Schneider PS, Galpin M. et al. Can thrombelastography predict venous thromboembolic events in patients with severe extremity trauma?. J Orthop Trauma 2016; 30 (06) 294-298
• 21 Blasi A, Molina V, Sanchez-Cabús S, Balust J, Garcia-Valdecasas JC, Taura P. Prediction of thromboembolic complications after liver resection for cholangiocarcinoma: is there a place for thromboelastometry?. Blood Coagul Fibrinolysis 2018; 29 (01) 61-66
• 22 Toukh M, Siemens DR, Black A. et al. Thromboelastography identifies hypercoagulability and predicts thromboembolic complications in patients with prostate cancer. Thromb Res 2014; 133 (01) 88-95
• 23 Thorson CM, Van Haren RM, Ryan ML. et al. Pre-existing hypercoagulability in patients undergoing potentially curative cancer resection. Surgery 2014; 155 (01) 134-144
• 24 Wikner J, Beck-Broichsitter BE, Schlesinger S. et al. Thromboelastometry: a contribution to perioperative free-flap management. J Craniomaxillofac Surg 2015; 43 (07) 1065-1071
• 25 Patel H, Srinivasa DR, Volod O, Wang ED, Kim EA. Rotational thromboelastometry derivative fibrinogen-platelet ratio predicts thrombosis in microsurgery. J Reconstr Microsurg 2021; 37 (09) 774-782
• 26 Hartmann J, Hermelin D, Levy JH. Viscoelastic testing: an illustrated review of technology and clinical applications. Res Pract Thromb Haemost 2022; 7 (01) 100031
• 27 Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005; 3 (09) 2039-2043
• 28 Walsh M, Kwaan H, McCauley R. et al. Viscoelastic testing in oncology patients (including for the diagnosis of fibrinolysis): review of existing evidence, technology comparison, and clinical utility. Transfusion 2020; 60 (Suppl. 06) S86-S100
• 29 Moore HB, Paniccia A, Lawson PJ. et al. Utility of viscoelastic assays beyond coagulation: can preoperative thrombelastography indices predict tumor histology, nodal disease, and resectability in patients undergoing pancreatectomy?. J Am Coll Surg 2018; 227 (01) 55-62
• 30 Liang H, Yang C-X, Li H, Wen X-J, Zhou Q-L, Gu M-N. The effects of preloading infusion with hydroxyethyl starch 200/0.5 or 130/0.4 solution on hypercoagulability and excessive platelet activation of patients with colon cancer. Blood Coagul Fibrinolysis 2010; 21 (05) 406-413
• 31 Goh KY-C, Tsoi W-C, Feng C-S, Wickham N, Poon WS. Haemostatic changes during surgery for primary brain tumours. J Neurol Neurosurg Psychiatry 1997; 63 (03) 334-338
• 32 Davies NA, Harrison NK, Sabra A. et al. Application of ROTEM to assess hypercoagulability in patients with lung cancer. Thromb Res 2015; 135 (06) 1075-1080
• 33 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372 (71) n71
• 34 Kim SY, Park JE, Lee YJ. et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 2013; 66 (04) 408-414
• 35 Sterne JA, Hernán MA, Reeves BC. et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919
• 36 Bagatin D, Šakić K, Bagatin T, Šturm D, Milošević M. Does rotation thrombelastometry (ROTEM) improve early prediction of coagulopathy in breast tumor?. Period Biol 2015; 117: 291-296
• 37 Allen CJ, Karcutskie CA, Zebib L. et al. Coagulation changes following combined ablative and reconstructive breast surgery. Plast Reconstr Surg 2016; 137 (06) 923e-930e
• 38 Haid M. Thromboelastographic distinction of malignant from benign breast masses: a preliminary report. South Med J 1977; 70 (07) 774-776
• 39 Francis JL, Francis DA, Gunathilagan GJ. Assessment of hypercoagulability in patients with cancer using the Sonoclot Analyzer and thromboelastography. Thromb Res 1994; 74 (04) 335-346
• 40 Goncalves JPN, de Waal GM, Page MJ. et al. The value of detecting pathological changes during clot formation in early disease treatment-naïve breast cancer patients. Microsc Microanal 2021; 27 (02) 425-436
• 41 Nielsen VG, Ley MLB, Waer AL, Alger PW, Matika RW, Steinbrenner EB. Plasmatic hypercoagulation in patients with breast cancer: role of heme oxygenase-1. Blood Coagul Fibrinolysis 2013; 24 (08) 809-813
• 42 Brema F, Queirolo MA, Canobbio L. et al. Hematologic parameters during treatment with high-dose medroxyprogesterone acetate. Tumori 1981; 67 (02) 125-128
• 43 Nielsen VG, Matika RW, Ley MLB. et al. Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer. Blood Coagul Fibrinolysis 2014; 25 (03) 248-253
• 44 Zavlin D, Steinberg AJ, Chegireddy V, Spiegel AJ. Two successful cases of DIEP flaps for breast reconstruction in patients with factor V Leiden. J Surg Case Rep 2018; 2018 (09) rjy231
• 45 Zavlin D, Chegireddy V, Jubbal KT, Agrawal NA, Spiegel AJ. Management of microsurgical patients using intraoperative unfractionated heparin and thromboelastography. J Reconstr Microsurg 2019; 35 (03) 198-208
• 46 Randi AM, Smith KE, Castaman G. von Willebrand factor regulation of blood vessel formation. Blood 2018; 132 (02) 132-140
• 47 Marfia G, Navone SE, Fanizzi C. et al. Prognostic value of preoperative von Willebrand factor plasma levels in patients with Glioblastoma. Cancer Med 2016; 5 (08) 1783-1790
• 48 Obermeier HL, Riedl J, Ay C. et al. The role of ADAMTS-13 and von Willebrand factor in cancer patients: results from the Vienna Cancer and Thrombosis Study. Res Pract Thromb Haemost 2019; 3 (03) 503-514
• 49 Pépin M, Kleinjan A, Hajage D. et al. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer. J Thromb Haemost 2016; 14 (02) 306-315
• 50 Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2 (02) 209-215
• 51 Miller B, Heilmann L. Hemorheologic variables in breast cancer patients at the time of diagnosis and during treatment. Cancer 1988; 62 (02) 350-354
• 52 von Tempelhoff GF, Heilmann L. Thrombosis and bemorbeology in patients with breast cancer and adjuvant chemotherapy. Clin Hemorheol Microcirc 1995; 15: 311-323
• 53 Chaari M, Ayadi I, Rousseau A. et al. Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability. BMC Cancer 2014; 14: 991
• 54 Falanga A, Schieppati F, Russo D. Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer. Semin Thromb Hemost 2015; 41 (07) 756-764
• 55 Mandalà M, Tondini C. Adjuvant therapy in breast cancer and venous thromboembolism. Thromb Res 2012; 130 (Suppl. 01) S66-S70
• 56 Levine MN, Gent M, Hirsh J. et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318 (07) 404-407
• 57 Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9 (02) 286-294
• 58 Lyman GH, Carrier M, Ay C. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5 (04) 927-974
• 59 Farge D, Debourdeau P, Beckers M. et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11 (01) 56-70
• 60 Hoffman M, Monroe III DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85 (06) 958-965
• 61 Ay C, Dunkler D, Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116 (24) 5377-5382
• 62 Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104 (12) 2822-2829
• 63 Simanek R, Vormittag R, Ay C. et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010; 8 (01) 114-120
• 64 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
• 65 Connolly GC, Khorana AA, Kuderer NM, Culakova E, Francis CW, Lyman GH. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res 2010; 126 (02) 113-118
• 66 Gerotziafas GT, Taher A, Abdel-Razeq H. et al; COMPASS–CAT Working Group. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist 2017; 22 (10) 1222-1231
• 67 Ay C, Vormittag R, Dunkler D. et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27 (25) 4124-4129
• 68 Arpaia G, Carpenedo M, Verga M. et al. D-dimer before chemotherapy might predict venous thromboembolism. Blood Coagul Fibrinolysis 2009; 20 (03) 170-175
• 69 Faille D, Bourrienne M-C, de Raucourt E. et al. Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process. Oncotarget 2018; 9 (41) 26453-26465
• 70 Ay C, Simanek R, Vormittag R. et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112 (07) 2703-2708
• 71 Posch F, Thaler J, Zlabinger G-J. et al. Soluble vascular endothelial growth factor (sVEGF) and the risk of venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study (CATS). Clin Cancer Res 2016; 22 (01) 200-206
• 72 van Es N, Hisada Y, Di Nisio M. et al. Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: a prospective cohort study. Thromb Res 2018; 166: 54-59
• 73 Bharthuar A, Khorana AA, Hutson A. et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res 2013; 132 (02) 180-184
• 74 Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T. et al. D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis. Br J Cancer 2018; 119 (08) 915-921
• 75 Khorana AA, Kamphuisen PW, Meyer G. et al. Tissue factor as a predictor of recurrent venous thromboembolism in malignancy: biomarker analyses of the CATCH trial. J Clin Oncol 2017; 35 (10) 1078-1085
• 76 van Es N, Louzada M, Carrier M. et al. Predicting the risk of recurrent venous thromboembolism in patients with cancer: a prospective cohort study. Thromb Res 2018; 163: 41-46
• 77 Attaran S, Somov P, Awad WI. Randomised high- and low-dose heparin prophylaxis in patients undergoing thoracotomy for benign and malignant disease: effect on thrombo-elastography. Eur J Cardiothorac Surg 2010; 37 (06) 1384-1390
• 78 Ren W, Chen M, Qiao Y, Zhao F. Global guidelines for breast cancer screening: a systematic review. Breast 2022; 64: 85-99